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Abstract
Background: Simple epithelial keratins appear early during embryonic development and are expressed in non-stratified,
ductal and pseudo-stratified epithelial tissues. CK19, the lowest molecular weight keratin, is also expressed in basal layer of
squamous epithelia of mucosal surfaces. Previous studies have shown that High Risk-Human Papilloma Virus (HR-HPV)
epithelial infection induces cell immortalization via E6 and E7 viral proteins and this, in turn, impairs cytokeratin expression
in cancerous cells lines derived from uterine cervix. Here, we demonstrate the possible relationship between HR-HPV+
oral/oropharyngeal cancer and the high levels of CK19 expression.
Methods: We analyzed 38 cases of Oral Squamous Cell Carcinomas/ Oro-Pharyngeal Squamous Cell Carcinomas (OSCCs/
OPSCCs) by Immunohistochemistry (IHC) using specific antibody (Ab) detecting CK19, by In Situ Hybridization (ISH) and
Polymerase Chain Reaction (PCR) based methods in order to define the HPV infectious status. We also evaluated the
variation of CK19 expression in UPCI-SCC-131 (HPV−) and UPCI-SCC-154 (HPV+) cell lines by immunocytochemistry (ICC)
and flow cytometry.
Results: CK19 OSCC/OPSCC score has been identified multiplying percentage of cancer expressing cells to staining
intensity. CK19 expression score in OSCCs/OPSCCs was very different between HPV+ (mean: 288.0 ± 24.3) and HPV−
cancers (mean: 66.2 ± 96.9). This difference was statistically significant (p < 0.001) with a strong evidence of correlation
(p < 0.001; Spearman’s R: +0.72). ROC curve analysis was performed on CK19 expression index related to HPV positivity.
Heterogeneous areas of immunoreactivity varying in percentage value, intensity and/or localization were observed in
normal epithelium, both perilesional and distant from the tumor with important differences between HR-HPV+ and
HR-HPV− carcinomas. By ICC and flow cytometry, the two analyzed cell lines were both CK19 positive but showed a
different level of expression, in particular it should be noted that the UPCI-SCC-154 (HPV+) cell line had a higher
expression than UPCI-SCC-131 (HPV−).
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Conclusions: In this study we demonstrated, for the first time, strong association between CK19 up-regulation and
HR-HPV+ OSCCs/OPSCCs. This test has a good accuracy. We identified ROC curve with a cut-off > 195 for HR-HPV positive
results (Sensitivity: 92.3 %; Specificity: 89.3 %). Furthermore, in OSCC/OPSCC, the CK19 test may be useful in identifying
HR-HPV infection, the latter being related to HPV E7 potential to disrupt normal cytokeratin expression pattern.
Keywords: HR-HPV, Immunohistochemistry, Cytokeratins
Introduction
According to epidemiological studies, a real shift in
OSCCs/OPSCCs aetiology may be one of the main rea-
sons of the recent reported improvements in survival of
a specific subgroup of patients, treated with radiotherapy
[1]. From the first report of Syrjanen et al. in 1983 [2],
several other Authors have identified HR-HPV in Head
and Neck cancers and confirmed the causal role of HPV
in a sub-group of oral-oropharyngeal cancers [3–7].
According to Bernard et al. the heterogeneous Papillo-
maviridae family now contains 29 genera formed by 189
papillomavirus types, isolated from humans, non-human
mammals, birds and reptiles. In particular 120 fully se-
quenced genotypes have been isolated from humans [8].
As a large group of host specific DNA virus, HPVs are
characterized by a considerable broad epithelial cell trop-
ism. Considering their potential risk to induce an invasive
cancer, almost 45 subtypes, isolated from the low genital
tract, have been all along grouped into high- and low- risk
HPV types [9]. Munoz et al. classified HPVs in three onco-
genic types: high risk viruses (HPV16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, 73 and 82), potential high risk vi-
ruses with a not well known oncogenic potential (HPV26,
53 and 66), and viruses with low oncogenic risk (types 6,
11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89) [10]. More
recently, the IARC Working Group has defined a carcino-
genic role for the HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and a probably carcinogenic potential for
the type 68 [11, 12]. Meta-analyses have proved that HPV
subtypes associated with head and neck squamous cell
cancer (HNSCCs) are broadly similar (but not completely
identical) with those classically observed in cervical car-
cinoma [13, 14]. This is likely to reflect not only a differ-
ence in viral life cycles in various and distant mucosal
locations, but also an associated diversity in mucosal local
immune responses [10, 15]. On the whole, HPV16, the
most common high risk HPV detected in cervical squa-
mous cell cancer (50-60 %), was also the most common
type detected in HNSCCs (85-95 %) [16].
HPVs exert their oncogenic potential by expressing E6
and E7 viral proteins in infected host cells.
These proteins affect cell cycle in terms of proliferation
induction and deregulation by targeting, respectively, p53
and pRB tumor suppressors, up to promote carcinogenesis.
In particular, it appears plausible that E7 oncogene is able
to redirect terminally differentiating epithelial cells to sup-
port viral DNA amplification, and in this way the gener-
ation and the maintenance of progeny virus [17].
Integration of HPV DNA into the host DNA, as key-
mechanism to induce high grade lesions and invasive
cancer [18, 19], is a topic well known in cervical carcin-
oma but with only few investigations in Head and Neck
cancers and numerous points of discussion. According
to recent observations, in oropharyngel cancers HPV is
almost exclusively not integrated and its carcinogenic ac-
tivity is due to E6/E7 oncoprotein expressed from epi-
somal viral status [20, 21].
The exact molecular mechanisms used by HPVs to
control the replication of their own genome and to pro-
mote and preserve their transcriptional activity to the
detriment of host infected cell are extremely tangled. Al-
though the viral mRNA translation process is intricately
tied to the differentiation program of the host epithelial
tissue, it is broadly acknowledged that the expressed
viral oncoproteins are highly able to induce keratino-
cytes immortalization and to enhance the disruption of
the normal cytokeratin (CK) expression pattern in strati-
fied squamous epithelium [22], in this way favoring the
stepwise process that leads to the onset of squamous cell
carcinoma. It has postulated that the preferred target of
HPV is the basal layer of the mucosal epithelium. In
this germinal layer, the interaction HPV-DNA and host
cell promotes cellular proliferation, radical change in
cellular metabolism and deregulation in the production
of cytokeratins. For example, in HPV infected uterine
cervix some Authors have reported deviations in the
expression of high molecular weight cytokeratins (HMW-
CKs) [23, 24].
Cytokeratins are proteins containing 10 nm intermedi-
ate filaments found in the intracytoplasmic cytoskeleton
of epithelial tissue, with a molecular weight of 40-68 kDa
[25]. They set up a complex family of proteins, including
at least 19 cytokeratins, divided into low versus high mo-
lecular weight (LMW-CKs vs HMW-CKs) solely based on
their molecular weight or according to their acidity and al-
kalinity in two specific types: the acidic type I (including
CK9-23) and the basic type II (including CK1-8) [26, 27].
Expression of these cytokeratins depends mainly on the
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epithelium type and on the status of epithelial terminal
differentiation and maturation. By applying this concept
also to the malignant epithelial counterparts, in surgical
pathology keratin IHC is considered a tool of immense
value widely used to assess cancer differentiation and
characterization.
According to the reported literature, normal oral mu-
cosa expresses cytokeratins 4, 5, 13, and 14 [28]. This
pattern seems to be kept or very similar to the normal
in benign epithelial lesions, while it is resulted irregular
and markedly altered in malignant tumors [29].
An early study by Kellokoski J, et al. evaluated by IHC
the distribution of cytokeratins 19, 14, 16 and 17 and 8
and 18 in 96 oral mucosal biopsies taken from women
with genital HPV infections. They observed a more effi-
cient and intense CK19 expression in the basal cell layer
of HPV DNA-positive samples, suggesting for the first
time that viral infection disturbs the keratinocyte differ-
entiation in the basal cells of oral epithelium accelerating
the production of LMW cytoskeletal protein [30].
Up to now analyses of the specific epithelial keratin
profile in HPV infected oral mucosa and in HPV re-
lated oral and oropharyngeal cancers are scanty and
questionable. Although it is well known that CK19 and/
or its fragment CYFRA 21–1 correlate with tumor pro-
gression both in the uterine cervix and in the upper
aerodigestive tract [31–33] and are statistically signifi-
cantly connected to patients outcome [34–36], the
exact role of CK19 in the genesis of HPV related oral
and oropharyngeal cancer requires further assessment
[37].
Aims of the present work have been firstly to detect
HR-HPV DNA in OSCC/OPSCC, secondly to value the
pattern of expression of CK19, and finally to demon-
strate the CK19 overexpression in neoplastic cells (com-
pared to the normal areas) in order to prove the possible
relationship between HR-HPV+ oral/oropharyngeal can-
cer and the high levels of CK19 expression.
Results
Our study-cohort was composed of 38 patients (11 fe-
males and 27 males), with a mean age of 64.83 years
(range:46–89). Characteristics of the patients group are
shown in Table 1.
The study also included 10 negative control cases of
non-neoplastic oral (n.5) and oropharyngeal mucosa (n.5):
these specimens were negative for HPV-DNA by ISH
assay using Inform HPV family-III (Ventana - Roche) and
Inform HPV family-II (Ventana - Roche) and consensus
primer PCR.
We have also included some control cases of uterine
cervix HR-HPV positive lesions (n.3 cases of High-grade
Squamous Intraepithelial Lesion (HSIL)), all of them
previously characterized for HPV by PCR followed by
direct sequencing.
Regarding immunohistochemical analysis, overall, the
average expression of CK19 in OSCC/OPSCC was 40.7 %
which resulted statistically significant when compared to
the corresponding normal, distant and/or peritumoural epi-
thelium (p < 0.05). Furthermore, considering the estimated
statistical cut-off value of 67 % of stained cells, we have
identified two cancer groups: CK19highOSCCs/OPSCCs (13
cases) and CK19lowOSCCs/OPSCCs (25 cases). Considering
the staining intensity of CK19 expressing cells, we observed
9 cases scored as 0, 3 cases scored as 1+, 3 cases scored as
2+ and 23 cases with score 3+. On this basis we subdivided
OSCCs/OPSCCs in two groups: CK19faintOSCCs/OPSCCs
(12 cases with score 0–1) and CK19strongOSCCs/OPSCCs
(26 cases with score 2–3). Moreover, according to the final
score (0–300), OSCCs/OPSCCs have been divided in two
classes: CK19high scoreOSCCs/OPSCCCs (15 cases with
score > 150) and CK19low scoreOSCCs/OPSCCs (23 cases
with score < 150). Finally, a wide variability in the intensity
and a prevalent distribution in the basal layers have been
Table 1 Baseline characteristics of the 38 patients with
OSCC/OPSCC
Variable Category N (%)
Age (years) < 64 18 (47.4)
≥ 64 20 (52.6)
Sex Male 27 (71)
Female 11 (29)






Differentiation Well 5 (13.1)
Moderate 18 (47.4)
Poor 15 (39.5)
Site OSCC (tongue, trigonous,
gums and cheeks) /OPSCC
(pharynx tonsils)
36 (94.7)
nodal metastases from OSCC 2 (5.3)
WADA 0 (absent) 9 (23.7)
1 (focal) 6 (15.8)
2 (moderate) 4 (10.5)
3 (intense) 11 (28.9
4 (MALT) 8 (21.1)
HR-HPV negative 28 (73.7)
positive 10 (26.3)
ND, not determined
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observed in the controls of normal oral and oropharyngeal
mucosa.
Immunohistochemical results were statistically correlated
with the clinico-pathological findings (sex, age, tumour site,
inflammatory infiltrate surrounding the tumour mass,
tumour stage and histological differentiation, peritumoral
dysplasia, presence of hyperkeratosis) and evaluated by
statistical univariate analysis (ANOVA). No statistically sig-
nificant correlations have been observed.
Regarding HPV detection in OSCC/OPSCC, among 38
cases, 10 were HR-HPV+ cancers (as evaluated by ISH
and/or consensus PCR) (Table 2): 6 cases were HPV16+,
1 case was infected by both HR- and LR-HPVs (HPV31/
44+), 1 case was HPV31+ and 1 case HPV56+; the
remaining positive case, at the ISH evaluation, showed
an integrated status for HR-HPV, but it has not been
possible to assess the viral genotype. Among the HR-
HPV+ cases as resulted by consensus PCR and/or ISH, 6
cases were investigated by ISH also to determine the in-
tegrated and/or episomic status of the virus: in 5 cases
the HR-HPV was associated to an integrated status; only
1 case resulted negative with cytoplasmic signals, but the
HR-HPV positivity was established by consensus PCR.
Finally, among the 28 HR-HPV− cancers, 2 were HPV6+
(Low Risk- Human Papilloma Virus, LR-HPV), 1 was
HPV53+ (Intermediate Risk- Human Papillloma Virus,
IR-HPV) and the remaining cases (n.25) were HPV−.
Regarding the correlation between CK19 expression
and HR-HPV infection in OSCC/OPSCC, we have noted
that CK19 expression scores were very different in the
two groups of analyzed cancers (HR-HPV+/HR-HPV−).
We obtained higher values in HR-HPV positive group
(mean: 288.0 ± 24.3) than in negative one (mean: 66.2 ±
96.9) (Figs. 1a and 2; Table 3). This difference was statis-
tically significant (p < 0.001) with a strong evidence of
correlation (p < 0.001; Spearman’s R: +0.72). We described
ROC curve with a cut-off > 195 for HR-HPV positive re-
sult (Sensitivity: 92.3 %; Specificity: 89.3 %; p < 0.001)
(Fig. 1b). High scores (270–300), high percentages (90–
100) of expressing cancer cells and a constant staining 3+
have been observed in all integrated HR-HPV+ OSCCs/
OPSCCs.
Heterogeneous areas of immunoreactivity varying in
percentage value, intensity and/or localization were ob-
served in normal epithelium, both perilesional and dis-
tant from the tumor.
In perilesional areas, in HR-HPV− cancers, we observed
CK19 positivity in 13 out 19 valuable cases (68.4 %) and a
generally moderate-strong staining, localized in all epithe-
lial layers (6 cases at basal level, 4 cases at the intermediate
layer and the remaining 3 cases in the upper layer).
In HR-HPV+ cancers we observed a constant expres-
sion of CK19 (positivity in 7 out 7 valuable cases; 100 %)
and a generally moderate-strong staining, mostly local-
ized to the upper layers.
The differences regarding CK19 staining localization
were statistically significant (p = 0.017) (Fig. 3, Table 4).
No statistical significance has been observed regarding
the difference in intensity of CK19 staining.
In mucosal areas distant from OSCCs/OPSCCs, in HR-
HPV− cancers we observed a prevalent absence of CK19
expression (58.9 %) and when present (n. 7 out 17 valu-
able cases; 41.1 %), we noted a wide variability in the in-
tensity of CK19 staining, distributed mostly in the basal
layers.
In HR-HPV+ OSCCs CK19 staining was always present
(positivity in 4 out 4 valuable cases; 100 %), generally
moderate-strong in intensity, localized equally at basal
and superficial epithelial layers. The differences regard-
ing CK19 staining intensity (Table 5A) and localization
(Fig. 4, Table 5B) were statistically significant (p = 0.032
for the intensity; p = 0.025 for the localization).
Finally, we measured the variation of CK19 expression
in UPCI-SCC-131 and UPCI-SCC-154 cell lines by ICC
and flow cytometry. The two cell lines were both posi-
tive to CK19 antibody but showed a different level of
expression, in particular it should be noted that the
UPCI-SCC-154 cell line had a higher level of expression,
characterized by strong intensity and a diffuse pattern;
on the other hand, UPCI-SCC-131 cell line showed a
lower level of expression, with mostly moderate, focally
strong intensity of the staining (Fig. 5).
UPCI-SCC-131 and UPCI-SCC-154 cell lines were also
characterized for intracellular expression of CK19 by
flow cytometry analysis. The cytofluorimetric pattern of
CK19 expression is well illustrated in Fig. 6. From the
flow cytometry histograms resulting from the two cell
lines, stained with the fluorescent antibody against CK19
with relative isotope control (Fig. 6a for UPCI-SCC-154,
Fig. 6b for UPCI-SCC-131 and from the overlay of the
two previous histograms (Fig. 6c), we have demonstrated
that the cell line UPCI-SCC-154 (HPV+) had a greater
Table 2 HR-HPV detection in OSCC/OPSCC, as evaluated by ISH
and/or consensus PCR
Case Origin Sex Age (ys) ISH PCR/Sequencing
1 AN M 74 HR-HPV integrated HR-HPV 16
2 AN M 59 HR-HPV integrated HR-HPV 16
3 AN F 61 negative HR-LR-HPV 31-44
4 PA F 60 ND HPV 56
5 PA M 75 ND HPV 16
6 FG M 64 ND HR-HPV 31
7 FG F 63 HR-HPV integrated ND
8 FG F 79 ND HR-HPV 16
9 NA M 67 HR-HPV integrated HR-HPV 16
10 NA F 69 HR-HPV integrated HR-HPV 16
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fluorescence value. Although the two studied cell lines
were both positive for CK19 expression, different rates
of positivity have been reported. The relative extent of
CK19 expression, as revealed by the mean fluorescence
intensity (MFI), varied among the analyzed cell lines, be-
ing lower for UPCI-SCC-131 (MFI = 60,62) in compari-
son to the UPCI-SCC-154 (MFI = 83,92) (Fig. 6d). The
absolute cell counting was performed on SSC/CK19 dot
plots (Fig. 6e-f ): both cell lines were positive for CK19.
Discussion
Since the HR-HPV subtypes are always more frequently
linked to aetiology of many human cancers including
oral and oropharyngeal cancer, an innovative approach
to the study of OSCC/OPSCC should be based on a bet-
ter understanding of the molecular viral background and
the relative interaction between virus and host cell. It
has well established that some HR-HPVs (in particular
HPV16) induce immortalization of keratinocytes and at
the same time the deregulation of the normal CK ex-
pression pattern in stratified squamous epithelium [22].
The investigation of CKs expression profile in HPV-
related OSCCs/OPSCCs and the study of its potential
value as possible predictor of viral infection and neoplas-
tic progression could allow to characterize a possible
evolutive morphologycal profile of malignancies.
Cytokeratin 19 (CK19), a 40 kDa acidic cytokeratin
(Type I), is normally expressed in stratified squamous
epithelium and it has been considered a marker of pre-
malignancy and susceptibility to cancers like the OSCC
[38].
Although we have not observed any type of correlation
between immunohistochemical CK19 expression and the
analyzed clinico-pathological findings, a recent study has
Fig. 1 CK19 expression score in HR-HPV+ and HR-HPV− OSCCs/OPSCCs. a. Differences in CK19 expression scores according to HR-HPV infectious
status. b. ROC curve with a strong evidence of correlation between HR-HPV positive result and CK19 expression (Sensitivity: 92.3 %; Specificity:
89.3 %; p <0.001) and (p <0.001; Spearman’s R: +0.72)
Fig. 2 Immunohistochemical expression of CK19 in HPV+ and HPV− OSCCs. a. Note the strong and diffuse immuostaining for CK19 in a representative
case of HPV related OSCC. b. A complete CK19 negative staining in HPV negative OSCC can be observed. Internal control is represented by
the positive staining for CK19 in salivary glands. (LSAB-HRP, nuclear counterstaining with haematoxylin; original magnification a, x40; b, x100)
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confirmed CK19 as a valid prognostic marker in human
OSCC and its over-expression as an important molecu-
lar event in pathogenesis of oral carcinoma [39].
Beforehand and similarly, other Authors have evalu-
ated the role of CK19 in OSCC, reporting different per-
centages of expression [40–42].
In our study, considering an average CK19 expres-
sion in cancer of 40.7 % and an estimated statistical
cut-off value of 67 % of stained cells, we have identi-
fied two cancer groups: CK19highOSCCs/OPSCCs and
CK19lowOSCCs/OPSCCs. According to staining intensity,
generally, it was mainly moderate or strong (3 cases
scored as 2+ and 23 cases with score 3+).
Heterogeneous areas of immunoreactivity varying in
percentage value, intensity and/or localization were also
observed in normal epithelium, both perilesional and
distant from the tumor.
In perilesional areas, we mostly observed a moderate-
strong positivity for CK19, distributed in all epithelial
layers (mostly at basal layer) and with lower percentages
in HR-HPV− cancers than in HR-HPV+ ones (68.4 % vs
100 %) where the marker preferentially was located to
the upper layers. In more distant areas, in HR-HPV−
OSCCs/OPSCCs CK19 staining was observed in 41.1 %
of cases with a wide variability in the intensity and dis-
tributed mostly in the basal layers, as observed in nor-
mal oral/oropharyngeal mucosa; differently, in HR-HPV+
OSCCs/OPSCCs CK19 was present in 100 % of cases,
generally moderate-strong in intensity and localized in
all epithelial layers.
Considering its low molecular weight, CK19 in normal
conditions should be mostly located in the basal/paraba-
sal layers [43]. In our sample in the perilesional areas, in
areas involved by preneoplastic changes, and also in
areas distant from the tumor but in the context of an
HR-HPV infected mucosa, as morphological sign of an
occurred disturb in the normal differentiation program,
we have observed that CK19 was distributed equally in
all epithelial layers, from the basal to the superficial ones
or preferentially in the upper levels.
Already in the past, it was suggested that when CK19
appears in the suprabasal cell layers in oral epithelium, it
might be a consequence of a delay or a disturbance in
the terminal differentiation, probably indicating reten-
tion of hyper-proliferative potential and acquisition of
cellular atypia associated to premalignancy [44]. On the
other hand, according to the idea that oral mucosa, as
well as genital cervix mucosa, is a target for frequent
frictions and irritations, thus needing a more rapid epi-
thelium regeneration, other Authors, since the far 90’s,
underlined that keratinocytes normally contain CK19
also in suprabasal layers [30, 45].
Anyway, it still remains to understand the exact role
of CK19 in the genesis of HPV related oral and oropha-
ryngeal cancer and how keratinocyte differentiation
could be involved in pathogenesis of HPV infection [46].
Table 3 Comparison between HR-HPV negative vs HR-HPV positive OSCCs/OPSCCs and CK19 expression score
(Independent Samples t-test) p value: < 0.001
Group N Mean CI 95 % Standard deviation Min Max
HR-HPV negative 28 66.214 30.332 - 102.097 96.873 0.0 300.0
HR-HPV positive 10 288.0 272.945 - 303.055 24.290 225.0 300.0
Fig. 3 CK19 staining expression and localization in perilesional mucosa in HPV−/HPV+ cancers. a. CK19 expression is evident in basal and
intermediate layer in dysplasia surrounding HPV−OSCC. b. Strong expression of CK19 in a basaloid OPSCC. Note the overhead mucosa with CK19
up-regulation and maturation disturbance. (LSAB-HRP, nuclear counterstaining with haematoxylin; original magnification a, x200; b, x40)
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In 1991 Kellokoski J et al. observed a statistically signifi-
cant difference between HPV-DNA and HPV-DNA
negative oral biopsies regarding CK19 staining, being the
last more intense in virus associated samples. They
interpreted their results suggesting that viral infection
could modify the keratinization of oral mucosa, disturb
the keratinocyte differentiation and exert proliferative
potential in basal cells, thus accelerating the production
of low molecular weight cytoskeletal protein [30]. From
1991 to nowadays, a long time of scientific silence about
the relationship between HPV and CK19 expression is
passed. In 2004 in a study performed on two cancer cell
lines (one derived from cervical squamous carcinoma,
the other one from a metastatic site of cervical carcinoma),
Favia et al. [47] have analyzed the interaction occurring be-
tween HPV type 16 E7 mRNA and the intermediate cyto-
keratin filaments 7 and 19 and reported data in favor of a
possible association between HPV16 E7 protein level and
CK19. The same Authors have highlighted the opposite ef-
fect of cytokeratins 7 and 19 on HPV16 E7 oncoprotein
expression, with CK7 involved in protecting and storing
the E7 transcript and CK19 assuring the viral mRNA
translation into the oncogenic product and, in turn, lead-
ing to the possibly related carcinogenic events [48].
Conclusions
Considering that HPV unrelated OSCCs/OPSCCs are
generally quite resistant to chemotherapeutic agents
while HPV related cancers are characterized by radio-
chemo sensitivity, HPV detection and in particular HR-
HPV identification are of basic importance in HNSCC
patients clinical management. Up to now, in spite of the
significant number and the types of molecular available
methods or their combinations, there is not a general
recognized agreement about the ‘golden standard’ identi-
fication test.
The currently performed techniques of viral detection
in clinical practice such as ISH, routinely IHC for viral
oncoprotein (E5-6-7) and p16-IHC test [16, 49] are con-
sidered not satisfactory when evaluated as HPV detect-
ing tests as used alone, for their low sensitivity [50, 51],
the limited antibodies availability (IHC), the low applic-
ability in clinical routine (ISH) and the low specificity
(p16). In particular, p16-IHC as diagnostic method has
caused much debate [52], since p16 over-expression
might be associated with functional pRb alterations that
are independent from the HPV infection [53] and even
not all HR-HPV-infected OPSCCs have lost the 9p21
allele encoding p16 [54].
Recently, in order to distinguish HPV+ versus HPV−
OSCCs/OPSCCs innovative techniques, as well as
SPF10 HPV DNA test, PGMY/GP nested PCR system,
quantitative E6 RNA PCR [55, 56] and c-DNA microar-
rays [57, 58], are merging and could be considered
highly sensitive molecular screening test with a very
high level of accuracy.
In an our previous study we have clearly demonstrated
that a combined triple method, consisting in p16-IHC/
ISH/Consensus PCR test, preserves the morphological
context of HPV-DNA signals in formalin-fixed, paraffin-
embedded (FFPE) samples and increases the overall spe-
cificity and sensitivity in HPV detection [59].
The presented study adds CK19 as a new interesting
marker able to determine a differential diagnosis among
HPV+ and HPV− OSCCs/OPSCCs. We have reported
higher values of CK19 expression in HR-HPV+ cancers
(CK19highOSCCs/OPSCCs; mean score: 288.0 ± 24.3)
than in negative ones (CK19lowOSCCs; mean score:
66.2 ± 96.9). This statistically significant difference (p <
0.001) suggests a possible association between HR-HPV
and CK19 expression.
Similar results have been obtained also by immuno-
cytochemical analyses performed on two SCC-cell lines
(differing for the HPV infectious status) and by flow cy-
tometry. Finally, these observations can be regarded as a
possible evidence of an interplay existing between HPV
oncogenic activity and keratinocyte differentiation.
We conclude that the routinely evaluation of an immu-
nohistochemical panel including p16, and CK19 should be
assessed by further investigations since these markers, ex-
clusively and in combination, could add useful informa-
tions concerning oral and oropharyngeal carcinogenesis
and improve the current diagnostic tools, allowing to
characterize a possible clinic-morphologycal profile of
oral/oropharyngeal cancer and its precancerous lesions.
Table 4 Comparison between HR-HPV negative vs HR-HPV
positive OSCCs/OPSCCs and CK19 staining expression and
localization in perilesional mucosa (Mann Whitney U Test)
Two-tailed p value: 0.017
Group N Median Avg Rank Min Max
HR-HPV negative 19 1.0 11.368 0.0 3.0
HR-HPV positive 7 3.0 19.286 1.0 3.0
Table 5 Comparison between HR-HPV negative vs HR-HPV
positive OSCCs/OPSCCs, CK19 staining expression (intensity in A,
localization in B) in distant mucosa (Mann Whitney U Test)
5A) Two-tailed p value: 0.032
Group N Median Avg Rank Min Max
HR-HPV negative 17 0.0 9.647 0.0 3.0
HR-HPV positive 4 3.0 16.75 2.0 3.0
5B) Two-tailed p value: 0.025
Group N Median Avg Rank Min Max
HR-HPV negative 17 0.0 9.588 0.0 3.0
HR-HPV positive 4 2.0 17.0 1.0 3.0
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Materials and methods
Study population
Upon approval by the Ethical Committee of the University
of Foggia, 38 subjects affected from OSCC/OPSCC were
randomly selected from 4 different Hospitals of the
Middle and South of Italy and enrolled in this study
(Institute of Pathological Anatomy, University of Foggia;
Department of Clinic Specialistic and Stomatological
Sciences, Polytechnic University of Marche, Ancona;
Institute of Oral Pathology, University of Napoli ‘Federico
II’; Department of Stomatological Sciences, University of
Palermo). All patients or their relatives gave their in-
formed written consent.
The cases have been randomly chosen from cohort
known for the HPV prevalence as previously published
[59–61] and were analyzed using FFPE materials coming
from surgery with curative intention; in addition, some
cases have been also analyzed using byoptical material ob-
tained in preoperative setting. All slides were reviewed by
2 pathologists (ASanto, GP) at the Institute of Pathological
Anatomy, University of Foggia, Foggia, Italy. Tumour
stage and grade were assigned according to the WHO
classification of malignant tumours of the head and neck
[62].
Finally, we have also selected an adequate group of
non-neoplastic oral (n.5) and oropharyngeal mucosa
(n.5) samples and some control cases of uterine cervix
HR-HPV HSILs (n.3) for the comparative statistical
evaluations. Characteristics of the group of the patients
are shown in Table 1, where we have reported clinical
data referring to patients’ sex, age, and histological
characteristics of the tumors (such as site, TNM sta-
ging, grading, infectious status). We have also assessed
the WADA grade, defined as the entity and the distri-
bution of inflammatory cells in the lamina propria and
in the submucosal tissue [63].
Finally, at the Institute of Pathological Anatomy,
University of Foggia, a total of 38 archival FFPE OSCCs/
OPSCCs were investigated by standard IHC for CK19, by
consensus HPV-DNA PCR methods to detect HPV infec-
tion and by ISH to study the viral integration status into
the host DNA.
Fig. 4 CK19 staining expression and localization in distant mucosa in HPV−/HPV+ cancers. a. CK19 expression was distributed mostly in the basal
layers in distant mucosa from HPV− OSCC. b. CK19 staining was generally moderate in intensity, localized both at basal and more superficial
epithelial layers in distant mucosa from HPV+ OSCC. (LSAB-HRP, nuclear counterstaining with haematoxylin; original magnification a, x200;
b, x200)
Fig. 5 Immunocytochemical expression of CK19 in HPV− OSCC cell line (SCC-131) and in HPV+ OSCC cell line (SCC-154). The two cell lines were
both positive to CK19 antibody but showed a different level of expression. a. Note that the UPCI-SCC-131 cell line showed a lower level of expression,
with mostly moderate, focally strong intensity of the staining. b. UPCI-SCC-154 cell line had a higher level of expression, characterized by
strong intensity and a diffuse pattern. (LSAB-HRP, nuclear counterstaining with haematoxylin; original magnification, x200)
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IHC
IHC was performed on 4 μm paraffin sections mounted
on poly-L-lysine-coated glass slides, by standard linked
streptavidin-biotin horseradish peroxidase (LSAB-HRP)
technique, using a specific monoclonal antibody against
CK19 (mAb clone A53-B/A2.26), by the Benchmark XT
autostainer (Ventana Medical Systems Inc, Tucson, AZ).
Cases were evaluated on the basis of percentage of posi-
tive cells and, considering a statistical cut-off of 67 %,
they were distinguished into two categories: CK19high-
OSCCs/OPSCCs and CK19lowOSCCs/OPSCCs. Then,
we have also evaluated the staining intensity, that has
been scored as follows: negative (0), faint (1), moderate
(2), strong (3). Finally, intensity staining has been multi-
plied to IHC percentage in order to obtain the final mo-
lecular expression score, ranging from zero to 300 units.
Appropriate positive and negative controls were run for
the tested antibody. On our OSCC/OPSCC samples, serial
sections, in addition to the neoplastic area, also included
perilesional areas and mucosal areas > 5 cm distant from
the tumor. Moreover, negative controls were performed
on other sections that comprised normal areas of removed
oral and oropharyngeal mucosa for surgical non-neoplastic
diseases; negative control slides without primary antibody
were also included. Positive control was executed on sec-
tions obtained from a case of infiltrating colon cancer.
Inter-rate reliability between the two investigators blindly
and independently examining the immunostained sections
was assessed by the Cohen’s K test, yielding K values higher
than 0.7.0 in almost all instances.
PCR analysis
HPV DNA was researched by nested PCR (MY/GP
primers), and HPV genotype was determined by direct se-
quencing of PCR fragments. Three types of control were
included in each reaction series: blank control, HPV-
neg.ve Wi cells as neg.ve control and HPV18 DNA-pos.ve
HeLa cells, in dilutions from 20,000–50,000 down to 2–5
HPV DNA copies, as pos.ve control. HPV DNA was amp-
lified by PCR assay using primers useful for samples with
a low copy number of HPV (MY09–MY11 primer pair in
combination with GP5–GP6 primer pair) as previously
Fig. 6 Representative FACS analysis. Histograms for SCC-154, and SCC-131. a, b Sample treated with antibody to CK19 conjugated with FITC and
with relative isotope control. c Overlay of Histograms. Fluorescence values on a logarithmic scale are shown on the x-axis and counts cells are
scored on the y-axis. d Table summarizing the differential CK19 expression on SCC cell lines. The CK19 percentage represents the fraction of cells
that linked the FITC-conjugated CK19 antibody, as compared to the total analyzed cell population. The mean fluorescence intensity (MFI) per cell
has also been reported. e-f) The plot of cell physical parameter (SCC versus CK19-FITC)
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demonstrated in current literature [64] and amplifications
were performed in a DNA thermal cycler (Mastercycler
gradient; Eppendorf, Hamburg, Germany); amplification
products were analyzed in 8 % polyacrylamide gel.
Sequencing analysis
HPV genotyping was based on direct sequencing of MY or
MY/GP PCR fragments. Amplification products were puri-
fied by Microcon YM-100 (Amicon-Millipore, Billerica,
MA); the sequence of both DNA strands was determined
by the BigDye Ready Reaction Kit in the automatic sequen-
cer ABI Prism 310 Analyzer (both from Perkin-Elmer
Applied Biosystems, Foster City, CA). Alignments were ob-
tained from the GenBank on-line BLAST server and HPV
sequences downloaded from the HPV database (http://
www.ijbcb.org/HPV/).
ISH for HPV DNA detection
ISH has been performed using the Benckmark® XT plate
and an indirect alkalin-phospathase antibody mediated de-
tection method. The hybridization signals were showed
with Tetrazole Blu and Fast Red nuclear counterstaining.
The commercially available Ventana kit includes the
following probes for HR-HPV: 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, e 66 (INFORM HPV III Family 16 Probe;
Ventana – Roche); and the following probes for LR-HPV:
6, 11 (Inform HPV Famly II 6 Probe; Ventana – Roche).
ISH evaluation
ISH signals have been evaluated on at least ten High
power fields at Olympus BX-41 optical microscope
(High Power Field, HPF, original magnification x 40).
OSCC/OPSCC cases showing prominent nuclear punc-
tuated (discreet dot-like) signals have been considered as
integrative (I). Cases with exclusive nuclear cluster sig-
nals as been evaluated as episomal (E). Cases showing a
prevalent nuclear cluster signals along with also focal
punctuated signals of integration have been evaluated as
mixed episomic-integrative (E-I). According to manufac-
turer instructions, artifacts or non-specific findings as
been considered the followings: non-cellular stromal
precipitates; cytoplasms of polymorphonuclear leuko-
cytes (PMNs), eosinophils, lymphocytes and endothelial
cells; non-specific staining of nucleoli.
Cell culture and treatment
Cell lines derived from OSCCs and normal keratinocytes
have been used for ICC and cytofluorimetric analyses.
The cell lines used were (1) UPCI-SCC-131 (originated
from a human oral squamous cell carcinoma of a 73-
year-old Caucasian man) (2) UPCI-SCC-154 (HPV+)
(originated from a human oral squamous cell carcinoma
of a 54-year-old Caucasian man). The cell lines were
purchased from the DSMZ, Braunschweig Germany.
The cell lines were grown in 90 % minimum essential
medium (MEM with Earle’s salts) supplemented with
non-essential amino acids, 10 % fetal bovine serum (FBS),
2 mM L-glutamine,1 % penicillin and 1 % streptomycin in
a humidified incubator containing 5 % CO2 at 37 °C.
ICC
Cells were grown on four-chamber tissue culture-treated
glass slides (Falcon Becton Dickinson, Labware, NJ,
USA) pre-coated with poly-L-lysine to enhance cell at-
tachment at a density of 5000 cells per well. Cultured
cells were rinsed with PBS, and finally fixed in alcohol.
Immunostaining was performed using LSAB-HRP tech-
nique and specific mouse monoclonal Ab anti CK19
(mAb clone A53-B/A2.26). Evaluations of the immuno-
cytochemical staining were performed separately by two
observers with at least 10 HPFs using optical microscopy.
Flow cytometry
To detect CK19 nonconfluent cultures were trypsinized into
single cell suspension, counted, washed with phosphate-
buffered saline (PBS), fixation and permeabilization by
intracell kit (immunostep, S.L. Avda). Then the cells were
incubated with FITC conjugated CK19 antibody ab87014 or
isotope antibody ab81197 (both from Abcam) as negative
control for 1 h. After washed twice with PBS, samples were
analyzed by FACSCalibur (Becton Dickinson).
Statistical analysis
All data have been analyzed by MedCalc 12.2.1.0 (for
Windows), SOFA Statistics 1.4.3 and R 2.11.1 (for Linux)
statistical softwares using Debian 7 and Windows Oper-
ating Systems.
Differences between groups were determined using the
Independent Samples t-test of average. Spearman’s
method and Point-biserial correlation coefficient were
used to study linear correlation and to determine the re-
lationship between CK19 expression and HR-HPV posi-
tivity (1 = HR-HPV integration positive signals; 0 =
negative ISH for HR-HPV). In order to select a relevant
CK19 cut-off score to identify HPV positive samples, Re-
ceiver Operating Characteristic (ROC) curve analysis
was carried out. The point on the curve, maximizing
sensitivity and specificity of CK19 expression score, was
selected as the cut-off score above which it was consid-
ered positive marker of HPV positivity. The expected
average value of the ROC area is 0.5 if there is no dis-
crimination between the groups. In order to distinguish
a real discrimination between the groups from the case
of no discrimination, a p-value was calculated. A small
p-value makes it unlikely that the ROC area can be rec-
onciled with the case of no discrimination. Only values
of p < 0.01 were considered significant.
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